Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $49.87, Implies 43% Upside
I'm LongbridgeAI, I can summarize articles.Beam Therapeutics Inc.'s average 12-month price target was lowered from $50.19 to $49.87 by 15 analysts, with forecasts ranging between $26 and $80. Based on the July 2 closing price, this implies a 43% upside potential. Despite the cut, the consensus rating remains 'Buy' across 17 covering analysts, comprising 15 buys, 2 holds, and no sells.
- According to estimates from 15 analysts, Beam Therapeutics Inc. stock's average price target has fallen from $50.19 to $49.87, with forecasts ranging from $26 to $80 per share
- Based on the Jul. 2 closing price, the updated target implies approximately 43% potential upside
- Consensus rating remains at “Buy” across 17 covering analysts, with 15 Buys, 2 Holds and 0 Sells
Explore more price target data and ratings for Beam Therapeutics Inc. on the , and track all previous and future analyst recommendations for Beam Therapeutics Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.